Q: What is Darzalex used for?

Darzalex is used to treat multiple myeloma and light chain amyloidosis .

Q: How does Darzalex work?

Targeting Cancer Cells Darzalex works by identifying and attaching to a protein called CD38. This protein is found in high amounts on the surface of multiple myeloma cells and some other types of blood cancer cells. Because CD38 is much more common on cancer cells than on healthy cells, the medication can specifically target the disease. Immune System Activation Once Darzalex binds to the CD38 protein, it acts like a signal for the body's immune system. It works through several different methods to eliminate the cancer: Immune-mediated cell death: The medication helps immune cells, such as natural killer cells and macrophages, recognize and kill the cancer cells. Direct cell death: Binding to the protein may trigger a process that causes the cancer cell to self-destruct. Complement-dependent cytotoxicity: The medication can activate a group of proteins in the blood called the complement system, which works to puncture and destroy the cancer cell membrane. By reducing the number of myeloma cells in the body, Darzalex helps slow the progression of the disease and may improve symptoms.

Q: What are the active ingredients in Darzalex?

The active ingredient in Darzalex is daratumumab .

Q: What are the side effects of Darzalex?

Common side effects of Darzalex may include: infusion reactions fatigue nausea and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Darzalex?

Darzalex belongs to the monoclonal antibody targeting CD38 drug class.

Q: What is the dosage of Darzalex and how do I take it?

Administration Darzalex is given by a healthcare professional in a hospital or clinic setting. It is not a medication you take at home. It can be administered in two ways: Intravenous (IV) infusion: The medication is delivered slowly into a vein. The first infusion usually takes several hours, while subsequent infusions may be shorter. Subcutaneous injection: The medication is injected under the skin, usually in the stomach area, over a few minutes. Dosing Schedule The frequency of treatments depends on the specific condition being treated and how long you have been receiving the medication. A typical schedule involves: Weekly doses for the first several weeks. Doses every two weeks for a period of time. Doses every four weeks for the remainder of the treatment. Pre-medication and Post-medication To reduce the risk of infusion or injection reactions, your healthcare provider will give you other medications shortly before each treatment. These may include: Antihistamines to prevent allergic reactions. Acetaminophen to reduce fever. Corticosteroids to reduce inflammation. You may also be prescribed medications to take at home after your treatment to help prevent delayed reactions. Missed Doses It is important to keep all appointments for your treatments. If you miss an appointment, contact your healthcare provider as soon as possible to reschedule your dose. The treatment is most effective when administered according to the prescribed schedule.

Q: Is Darzalex safe during pregnancy and breastfeeding?

Pregnancy There is limited information regarding the use of Darzalex in pregnant women. Because Darzalex is a monoclonal antibody, it can cross the placenta and may affect the developing fetus. Based on its mechanism of action, it could cause fetal harm, including a decrease in certain immune cells in the newborn. Healthcare providers typically recommend the following for individuals who can become pregnant: A pregnancy test should be performed before starting treatment. Effective contraception should be used during treatment and for at least 3 months after the final dose. If Darzalex is used in combination with other medications, such as lenalidomide, thalidomide, or pomalidomide, additional strict pregnancy prevention requirements must be followed. Those drugs are known to cause severe birth defects and have specific safety programs in place. Breastfeeding It is not known whether Darzalex passes into human breast milk or how it might affect a nursing infant. Because many antibodies are excreted in human milk and there is a potential for serious adverse reactions in the infant, breastfeeding is generally not recommended during treatment with Darzalex. Patients should discuss the best way to feed their baby with their healthcare provider.

Q: What is the FDA approval status of Darzalex?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Darzalex in November 2015. It was the first monoclonal antibody approved to treat multiple myeloma. Since its initial approval, the FDA has expanded its indications to include use in combination with various other therapies for patients at different stages of the disease, including those who are newly diagnosed. Approved Indications Darzalex is approved for the treatment of adult patients with: Newly diagnosed multiple myeloma, used in combination with other medications for patients who are or are not eligible for a stem cell transplant. Relapsed or refractory multiple myeloma, used as a single agent or in combination with other standard cancer treatments. Light chain (AL) amyloidosis, specifically the subcutaneous formulation, in combination with other therapies. Safety Monitoring and Communications The FDA monitors the safety of Darzalex through post-marketing surveillance. In 2020, the FDA identified potential signals of serious risks, including the risk of hepatitis B virus reactivation in patients receiving daratumumab. Regulatory guidelines recommend that healthcare providers screen patients for hepatitis B infection before starting treatment and monitor for signs of reactivation during therapy. Darzalex does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program required by the FDA.

Question 1

What is Darzalex?

Accepted Answer

Darzalex is a prescription medication that contains the active ingredient daratumumab. It belongs to a class of drugs known as monoclonal antibodies, which are laboratory-made proteins designed to mimic the immune system's ability to fight harmful cells.

The medication works by binding to a specific protein called CD38, which is often found in high amounts on the surface of certain cancerous cells. Once attached, it helps the body's immune system recognize and destroy these targeted cells while also potentially interfering with their growth.

Question 2

What is Darzalex used for?

Accepted Answer

Darzalex is used to treat multiple myeloma and light chain amyloidosis.

Question 3

How does Darzalex work?

Accepted Answer

Targeting Cancer Cells

Darzalex works by identifying and attaching to a protein called CD38. This protein is found in high amounts on the surface of multiple myeloma cells and some other types of blood cancer cells. Because CD38 is much more common on cancer cells than on healthy cells, the medication can specifically target the disease.

Immune System Activation

Once Darzalex binds to the CD38 protein, it acts like a signal for the body's immune system. It works through several different methods to eliminate the cancer:

Immune-mediated cell death: The medication helps immune cells, such as natural killer cells and macrophages, recognize and kill the cancer cells.
Direct cell death: Binding to the protein may trigger a process that causes the cancer cell to self-destruct.
Complement-dependent cytotoxicity: The medication can activate a group of proteins in the blood called the complement system, which works to puncture and destroy the cancer cell membrane.

By reducing the number of myeloma cells in the body, Darzalex helps slow the progression of the disease and may improve symptoms.

Question 4

What are the active ingredients in Darzalex?

Accepted Answer

The active ingredient in Darzalex is daratumumab.

Question 5

What are the side effects of Darzalex?

Accepted Answer

Common side effects of Darzalex may include:

infusion reactions
fatigue
nausea
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Darzalex?

Accepted Answer

Darzalex belongs to the monoclonal antibody targeting CD38 drug class.

Question 7

What is the dosage of Darzalex and how do I take it?

Accepted Answer

Administration

Darzalex is given by a healthcare professional in a hospital or clinic setting. It is not a medication you take at home. It can be administered in two ways:

Intravenous (IV) infusion: The medication is delivered slowly into a vein. The first infusion usually takes several hours, while subsequent infusions may be shorter.
Subcutaneous injection: The medication is injected under the skin, usually in the stomach area, over a few minutes.

Dosing Schedule

The frequency of treatments depends on the specific condition being treated and how long you have been receiving the medication. A typical schedule involves:

Weekly doses for the first several weeks.
Doses every two weeks for a period of time.
Doses every four weeks for the remainder of the treatment.

Pre-medication and Post-medication

To reduce the risk of infusion or injection reactions, your healthcare provider will give you other medications shortly before each treatment. These may include:

Antihistamines to prevent allergic reactions.
Acetaminophen to reduce fever.
Corticosteroids to reduce inflammation.

You may also be prescribed medications to take at home after your treatment to help prevent delayed reactions.

Missed Doses

It is important to keep all appointments for your treatments. If you miss an appointment, contact your healthcare provider as soon as possible to reschedule your dose. The treatment is most effective when administered according to the prescribed schedule.

Question 8

Is Darzalex safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the use of Darzalex in pregnant women. Because Darzalex is a monoclonal antibody, it can cross the placenta and may affect the developing fetus. Based on its mechanism of action, it could cause fetal harm, including a decrease in certain immune cells in the newborn.

Healthcare providers typically recommend the following for individuals who can become pregnant:

A pregnancy test should be performed before starting treatment.
Effective contraception should be used during treatment and for at least 3 months after the final dose.

If Darzalex is used in combination with other medications, such as lenalidomide, thalidomide, or pomalidomide, additional strict pregnancy prevention requirements must be followed. Those drugs are known to cause severe birth defects and have specific safety programs in place.

Breastfeeding

It is not known whether Darzalex passes into human breast milk or how it might affect a nursing infant. Because many antibodies are excreted in human milk and there is a potential for serious adverse reactions in the infant, breastfeeding is generally not recommended during treatment with Darzalex. Patients should discuss the best way to feed their baby with their healthcare provider.

Question 9

What forms and strengths does Darzalex come in?

Accepted Answer

Darzalex is provided as a sterile, preservative-free solution for intravenous use. The liquid is clear to opalescent and may range from colorless to pale yellow.

Intravenous Infusion: This medication is supplied in single-dose vials. It must be diluted with a compatible solution by a healthcare professional before being administered into a vein.

Darzalex is not available in oral forms, such as tablets or capsules, and is only administered in a clinical setting by trained medical staff.

Question 10

What is the FDA approval status of Darzalex?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Darzalex in November 2015. It was the first monoclonal antibody approved to treat multiple myeloma. Since its initial approval, the FDA has expanded its indications to include use in combination with various other therapies for patients at different stages of the disease, including those who are newly diagnosed.

Approved Indications

Darzalex is approved for the treatment of adult patients with:

Newly diagnosed multiple myeloma, used in combination with other medications for patients who are or are not eligible for a stem cell transplant.
Relapsed or refractory multiple myeloma, used as a single agent or in combination with other standard cancer treatments.
Light chain (AL) amyloidosis, specifically the subcutaneous formulation, in combination with other therapies.

Safety Monitoring and Communications

The FDA monitors the safety of Darzalex through post-marketing surveillance. In 2020, the FDA identified potential signals of serious risks, including the risk of hepatitis B virus reactivation in patients receiving daratumumab. Regulatory guidelines recommend that healthcare providers screen patients for hepatitis B infection before starting treatment and monitor for signs of reactivation during therapy.

Darzalex does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program required by the FDA.

Question 11

What should I know about Darzalex and cost?

Accepted Answer

Factors Influencing Cost

Several factors determine the total cost of treatment with Darzalex:

Dosage and Frequency: The amount of medication needed is often based on the patient's body weight. Additionally, the frequency of doses changes throughout the treatment course, typically starting weekly and moving to every few weeks.
Administration Fees: Because Darzalex is administered by a healthcare professional as an intravenous infusion or a subcutaneous injection, there are costs associated with the clinical visit and the administration process itself.
Treatment Setting: Costs may differ depending on whether the medication is received at a hospital outpatient department, a private clinic, or a specialized infusion center.

Insurance and Financial Support

Most insurance plans, including Medicare and private health insurance, provide coverage for Darzalex when it is medically necessary. However, patients may still be responsible for out-of-pocket expenses such as deductibles, co-insurance, or copayments.

Financial assistance programs may be available through the drug manufacturer or third-party organizations to help eligible patients manage these costs. These programs often include savings cards for those with commercial insurance or patient assistance programs for those who are uninsured or underinsured.

Generic and Biosimilar Availability

Darzalex is a brand-name biologic medication. Currently, there are no lower-cost biosimilar or generic versions available on the market. Biologic drugs are complex to manufacture, which generally contributes to their higher cost compared to traditional chemical drugs.

Darzalex

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Darzalex

Hospitals.net Disclosure